Risperidone is a second generation antipsychotic agent,
with potent serotonin 5-HT2A and dopamine D2 receptor blocking
effects. Specifically, risperidone possesses a unique balance of serotonin
and dopamine antagonism, namely that its affinity for 5-HT2A receptors
is significantly greater than its affinity for D2 receptors. Risperidone is
well-established medication, with the proven effects on positive and negative
symptoms of schizophrenia. The aim of research was to establish the effectiveness
and safety of risperidone in patients with schizophrenia.